Avid followers of the dealmaking frenzy in the pharmaceutical sector might want to take a look at piece on Roche Holding published a few days ago by dealReporter.
The "intelligence" service got some good quotes from Roche chief financial officer Alan Hippe, who told dealReporter that the Swiss pharmaceutical giant is still/back in the market for acquisitions in areas that don't overlap with existing drug development plans/pipelines.
Showing posts with label dealReporter. Show all posts
Showing posts with label dealReporter. Show all posts
Subscribe to:
Comments (Atom)